Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
about
The aetiological role of human papillomavirus in oesophageal squamous cell carcinoma: a meta-analysisRome Consensus Conference - statement; human papilloma virus diseases in malesEstimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccinationRandomized controlled trials of interventions to prevent sexually transmitted infections: learning from the past to plan for the future.American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancerCost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United StatesRole of the microbiome in non-gastrointestinal cancersHuman papillomavirus-associated cancers: A growing global problemPreventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology GuidelineVaccine adjuvants as potential cancer immunotherapeuticsVaccine Adjuvants: from 1920 to 2015 and BeyondMolecular cancer prevention: Current status and future directionsSafety and Efficacy Data on Vaccines and Immunization to Human PapillomavirusHuman papillomavirus vaccination in low-resource countries: lack of evidence to support vaccinating sexually active womenAmerican Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.Prevalence of Human Papillomavirus in Oropharyngeal Cancer: A Systematic ReviewHuman papillomavirus vaccination: a case study in translational scienceHuman papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysisVIN usual type-from the past to the futureHuman papilloma virus infection in head and neck cancerLessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteinsDisruption of Bcl-2 and Bcl-xL by viral proteins as a possible cause of cancerHPV vaccine: Current status and future directionsTrial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapyMajor clinical research advances in gynecologic cancer in 2015Current global status & impact of human papillomavirus vaccination: Implications for IndiaSafety of human papillomavirus vaccines: a reviewPopulation-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysisCross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic VaccinesAre we missing an opportunity for cancer prevention? Human papillomavirus vaccination for survivors of pediatric and young adult cancersAnalysis of the papillomavirus E2 and bromodomain protein Brd4 interaction using bimolecular fluorescence complementationCapsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approachEvolutionary medicine: its scope, interest and potentialUse of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoproteinCapsomer vaccines protect mice from vaginal challenge with human papillomavirusImmune Adjuvant Effect of Molecularly-defined Toll-Like Receptor LigandsEffect of race/ethnicity on participation in HIV vaccine trials and comparison to other trials of biomedical preventionAge-specific prevalence of HPV16/18 genotypes in cervical cancer: A systematic review and meta-analysis.Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections.DermaVir: a plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS.
P2860
Q21132685-F74D3583-CEC3-4E58-B782-54D7858BA153Q21257274-D909CE50-3B03-431B-B795-89C15C87E810Q21261267-B6F5FA97-5004-49A5-8D0B-E3E5569E0915Q24600011-3E698750-EB77-49A4-8A7E-58EA4F40812CQ24607403-D7A5AE74-DE3B-45BD-AAD4-E10F636486F8Q24655328-01075219-8B18-4D75-992E-9DB3F1321769Q26747710-2289F5C3-4E66-4201-AFCE-29AA92B64A2BQ26748962-9698633C-E535-4E72-94BB-97AFCCEC4B3CQ26749285-6C2C504B-4C79-4A26-8AC5-68A55CEC9FEFQ26752522-7B4A3CAC-52AB-4F46-9E11-3465D48C4F0BQ26783879-DB85EDAB-9EEC-4D09-A8A3-4EEA5AFD9189Q26797207-6981AEA4-CAB2-4E7E-8CAE-F9B3D128A9E7Q26799574-279A7642-451A-40EE-B3D1-680DCA64A919Q26824062-8E61004E-DEE2-45D4-B6C0-1EF13638338DQ26828840-53D53E9E-F38A-43C4-B576-F216CA286118Q26851922-A156D940-A0EB-44A8-99D2-B4492027125FQ26853556-01A50F88-B23F-43DE-85B4-414DCDBE6E13Q26863193-9985FFFE-30B3-4B64-BB51-382E24CB5E5FQ26865303-7F71A759-E07C-4E82-964A-481BF9336C6AQ26996504-76D96D56-FBBE-4C1D-8B82-2F02BE499371Q27013018-234F03D9-EC88-46C3-A320-ABFB2B1E1A02Q27020978-0F939682-5892-45FC-9143-4944AA1B5F50Q27026524-530D3B3C-A093-4B2B-9E78-929321B0A8F8Q28067939-19A766F7-7B62-4FCB-AE97-54B4604D5F2CQ28077183-D1139C10-7110-4B72-85BE-4ED587233CB2Q28079776-A2A554D2-5EE6-4F88-815D-2C611EB96C29Q28082119-56F7C3D5-7811-48F5-B4F8-36E0BF468D56Q28084924-6844BDDB-03C4-4635-935D-99A507456FA0Q28085724-CF0A6F9B-7319-4C50-B70A-D6EAA836ECB4Q28088322-83BCF977-061E-4C7A-A6CD-D3D9B1DF01A9Q28534628-B6F6B46B-65E9-4669-A50B-03D4D3A8B510Q28607775-F84AC249-9FF1-4BCF-BD3A-908191671DFEQ28715053-5254D7BA-B9DF-4FCF-B9B4-DA95D1D06C5DQ28730561-96C1C1C2-0DEA-4679-91DB-E04151F96993Q28743261-31883F58-901E-4898-8336-F060EFD9AE0AQ28972540-0E74ACF0-0C8F-437A-9D49-E77E29D45D2EQ30206105-4FAF1E31-B1A7-4E45-A6CE-9BFF55117E57Q30252012-925A3E35-42B9-4791-9655-D88FD445149BQ30353668-7233870C-9852-49AC-A03A-F3F45D0E66EFQ30408029-ABBAECF8-BAF6-4E16-AECA-1C18220BECE5
P2860
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Efficacy of human papillomavir ...... andomised study in young women
@ast
Efficacy of human papillomavir ...... andomised study in young women
@en
Efficacy of human papillomavir ...... andomised study in young women
@nl
type
label
Efficacy of human papillomavir ...... andomised study in young women
@ast
Efficacy of human papillomavir ...... andomised study in young women
@en
Efficacy of human papillomavir ...... andomised study in young women
@nl
prefLabel
Efficacy of human papillomavir ...... andomised study in young women
@ast
Efficacy of human papillomavir ...... andomised study in young women
@en
Efficacy of human papillomavir ...... andomised study in young women
@nl
P2093
P50
P3181
P1433
P1476
Efficacy of human papillomavir ...... andomised study in young women
@en
P2093
A Szarewski
B Romanowski
C M Wheeler
D Descamps
H Kitchener
P304
P3181
P356
10.1016/S0140-6736(09)61248-4
P407
P577
2009-07-25T00:00:00Z